The FDA has approved a supplemental biologics application for Leqembi Iqlik subcutaneous injection for maintenance dosing in ...

FDA approves Leqembi Iqlik as a weekly subcutaneous injection for Alzheimer's treatment, enhancing patient convenience and ...

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of ...

While the approval of Leqembi Iqlik bodes well for Biogen and Eisai’s planned application for a subcutaneous induction ...

The anti-amyloid maintenance therapy offers a once-weekly, subcutaneous option after 18 months of intravenous treatment.

By Stephanie Brown HealthDay ReporterTUESDAY, Sept. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

The FDA has approved the BLA for Leqembi Iqlik, a once weekly lecanemab-irmb SC injection, for maintenance dosing to treat Alzheimer disease.

The US Food and Drug Administration (FDA) has approved a new version of an Alzheimer’s disease drug that can be given as a ...

Migaldendranib (MGB) is a new class of targeted nanomedicine for the treatment of diabetic macular edema (DME) and neovascular age-related ...

Subcutaneous injections do not require a port like an IV, eliminating the risk for port-related complications such as infections.

The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance ...